Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

Molecular Pathways: ROS1 Fusion Proteins in Cancer

(2013) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Identification of recurrentFGFR3fusion genes in lung cancer through kinome-centred RNA sequencing

(2013) Ian J Majewski et al.   JOURNAL OF PATHOLOGY

Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

(2013) Daehwan Kim et al.   GENOME BIOLOGY

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

(2013) Todd M. Pitts et al.   Frontiers in Pharmacology

Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer

(2012) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

The transcriptional landscape and mutational profile of lung adenocarcinoma

(2012) J.-S. Seo et al.   GENOME RESEARCH

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing

(2011) Y. S. Ju et al.   GENOME RESEARCH

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

Integrative analysis of the melanoma transcriptome

(2010) M. F. Berger et al.   GENOME RESEARCH

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

(2009) Andreas Gnirke et al.   NATURE BIOTECHNOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE